Related Experiment Video
Updated: May 9, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma
María-Victoria Mateos1, Miguel-Teodoro Hernández, Pilar Giraldo
1Hospital Universitario de Salamanca, Instituto de Biología Molecular y Celular del Cáncer, Universidad de Salamanca-Consejo Superior de Investigaciones Científicas, Salamanca, Spain.
The New England Journal of Medicine
|August 2, 2013
Summary
Early treatment for high-risk smoldering multiple myeloma significantly delays disease progression and improves overall survival compared to observation. This intervention offers a new standard of care for patients with this pre-malignant condition.
Area of Science:
- Hematology
- Clinical Oncology
- Myeloma Research
Background:
- Standard care for smoldering multiple myeloma (SMM) is observation, which fails to identify high-risk patients.
- Early intervention strategies are needed to improve outcomes for high-risk SMM patients.
Purpose of the Study:
- To evaluate the efficacy of early treatment versus observation in patients with high-risk smoldering multiple myeloma.
- To assess the impact of early treatment on time to progression, overall survival, and response rates.
Main Methods:
- A randomized, open-label, phase 3 trial involving 119 high-risk smoldering myeloma patients.
- Patients were assigned to either an induction and maintenance treatment regimen (lenalidomide and dexamethasone) or observation.
- Primary endpoint was time to progression; secondary endpoints included overall survival and safety.
Main Results:
- Median time to progression was significantly longer in the treatment group (not reached vs. 21 months).
- The 3-year survival rate was higher in the treatment group (94% vs. 80%).
- High response rates (79% after induction, 90% during maintenance) were observed with manageable toxicity.
Conclusions:
- Early treatment for high-risk smoldering multiple myeloma delays progression to symptomatic disease.
- Early intervention with lenalidomide and dexamethasone improves overall survival in this patient population.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:25Dosage Regimen: Multiple Oral Dosage
Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:01Dosage Regimen: Fixed Dose
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...